Compound Comparison

Semax vs Selank: Comparing Two Neuropeptide Research Compounds

Last updated: March 31, 2026

Semax and Selank are two synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both have been studied extensively in preclinical models for their effects on brain function, and both are approved as prescription medications in Russia — Semax for cognitive and neuroprotective applications, Selank for anxiolytic purposes. Despite their superficial similarities as neuropeptides, they operate through fundamentally different mechanisms and target different neurochemical systems.

This article provides a side-by-side comparison of their mechanisms, research profiles, and the published evidence base for each compound. Understanding their differences is essential for researchers selecting the appropriate tool for specific neurochemical investigations.

Origins & Chemical Profiles

Semax: The ACTH Fragment

Semax is a synthetic analogue of ACTH(4-10) — a fragment of adrenocorticotropic hormone. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro, with a molecular weight of 887 Da. The Pro-Gly-Pro C-terminal extension was added to increase metabolic stability beyond what the native ACTH fragment provides. Semax was developed primarily as a nootropic and neuroprotective research tool.

Selank: The Tuftsin Analogue

Selank is a synthetic analogue of tuftsin — a naturally occurring immunostimulatory peptide. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a molecular weight of 751.88 g/mol. Like Semax, it carries a Pro-Gly-Pro stabilizing extension. However, its base peptide (tuftsin) comes from the immune system rather than the endocrine system, which gives Selank a fundamentally different pharmacological profile.

Mechanism of Action: How They Differ

Semax — Neurotrophic & Dopaminergic

Semax's primary mechanism centers on BDNF (Brain-Derived Neurotrophic Factor) upregulation. BDNF is one of the most important growth factors in the brain — it supports the survival of existing neurons, encourages the growth of new neurons and synapses, and is considered critical for learning and memory formation. Published research demonstrates that Semax significantly increases BDNF expression in hippocampal and cortical tissue.

Beyond BDNF, Semax modulates the dopaminergic and serotonergic systems. Research shows it influences the turnover of dopamine and serotonin in the brain, which are the neurotransmitter systems most associated with motivation, focus, reward processing, and mood regulation. This dual neurotrophic + monoamine profile is what gives Semax its characterization as a cognitive-enhancing compound in the research literature.

Semax also demonstrates neuroprotective properties in ischemic models — studies show it reduces neuronal damage when brain tissue is deprived of blood flow, likely through a combination of BDNF-mediated survival signaling and anti-inflammatory effects.

Selank — GABAergic & Anxiolytic

Selank's primary mechanism involves GABAergic modulation. GABA (gamma-aminobutyric acid) is the brain's main inhibitory neurotransmitter — it reduces neuronal excitability and is the system targeted by anxiolytic medications like benzodiazepines. Published research demonstrates that Selank modulates gene expression in neurons involved in GABA signaling, effectively enhancing GABAergic tone without directly binding GABA receptors.

This indirect modulation is significant because it distinguishes Selank from benzodiazepines mechanistically. Where benzodiazepines directly potentiate GABA-A receptors (producing tolerance, dependence, and sedation), Selank appears to influence the expression and regulation of GABA-related genes — a more subtle, upstream effect that published research associates with anxiolytic activity without the sedative or dependence profiles of direct receptor agonists.

Selank also upregulates BDNF, but its primary characterization in the literature is as an anxiolytic rather than a cognitive enhancer. It additionally retains some of the immunomodulatory properties of its parent compound tuftsin, with published studies showing effects on cytokine balance and immune cell function.

Head-to-Head Comparison

Combination Research

Because Semax and Selank operate through largely non-overlapping mechanisms (dopaminergic/neurotrophic vs GABAergic/anxiolytic), they are sometimes studied in combination. The rationale is that cognitive enhancement (Semax) may be more effectively expressed in the absence of anxiety-related interference (Selank). Published research on the combination is limited compared to individual compound studies, but the mechanistic logic is well-supported by the existing literature on each compound independently.

Research Limitations

The majority of published research on both Semax and Selank originates from Russian research institutions. While the studies are peer-reviewed and indexed in PubMed, the research landscape would benefit from independent replication in Western laboratory settings. Large-scale human clinical trials meeting FDA standards have not been conducted for either compound. Researchers should consult the original publications for specific methodological details relevant to their applications.